AbbVie, Pfizer gain FDA OK for novel antibiotic
Summary:
The FDA approved Emblaveo, a novel antibiotic from AbbVie and Pfizer, for treating complex intra-abdominal infections. This drug, combining aztreonam and avibactam, targets resistant gram-negative bacteria.
Immune drugmakers Alumis and Acelyrin to merge
Summary:
Biotech firms Alumis and Acelyrin announced a merger, combining their drug pipelines and $737M cash reserves. The deal unites three clinical-stage drugs, focusing on autoimmune conditions.
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Summary:
Bristol Myers Squibb reported positive trial results for Breyanzi in treating marginal zone lymphoma. This CAR T cell therapy shows promise as their fifth successful cancer treatment type.
OpenAI’s ‘deep research’ tool: is it useful for scientists?
Summary:
OpenAI launched ‘deep research’, a tool that creates detailed, cited reports from web sources. While promising for literature reviews, scientists note it needs fact-checking and can make mistakes, like other AI tools.
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
Summary:
Bain Capital acquired Mitsubishi Tanabe Pharma for $3.3 billion, marking a major investment in Japan’s pharmaceutical sector. The deal comes as Japan eases drug approval regulations for international companies.
